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Martina Aerni17, Valeria Gaia18, Helke van Dessel19, Greetje A. Kampinga20,21, Claudia Müller22,
Claudia Daubenberger23,24, Valentin Pflüger5 and Adrian Egli1,2*

Abstract
Background: Klebsiella spp. are opportunistic pathogens which can cause severe infections, are often multi-drug
resistant and are a common cause of hospital-acquired infections. Multiple new Klebsiella species have recently
been described, yet their clinical impact and antibiotic resistance profiles are largely unknown. We aimed to explore
Klebsiella group- and species-specific clinical impact, antimicrobial resistance (AMR) and virulence.
Methods: We analysed whole-genome sequence data of a diverse selection of Klebsiella spp. isolates and identified
resistance and virulence factors. Using the genomes of 3594 Klebsiella isolates, we predicted the masses of 56
ribosomal subunit proteins and identified species-specific marker masses. We then re-analysed over 22,000 MatrixAssisted Laser Desorption Ionization - Time Of Flight (MALDI-TOF) mass spectra routinely acquired at eight
healthcare institutions in four countries looking for these species-specific markers. Analyses of clinical and
microbiological endpoints from a subset of 957 patients with infections from Klebsiella species were performed
using generalized linear mixed-effects models.
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Results: Our comparative genomic analysis shows group- and species-specific trends in accessory genome
composition. With the identified species-specific marker masses, eight Klebsiella species can be distinguished using
MALDI-TOF MS. We identified K. pneumoniae (71.2%; n = 12,523), K. quasipneumoniae (3.3%; n = 575), K. variicola
(9.8%; n = 1717), “K. quasivariicola” (0.3%; n = 52), K. oxytoca (8.2%; n = 1445), K. michiganensis (4.8%; n = 836), K.
grimontii (2.4%; n = 425) and K. huaxensis (0.1%; n = 12). Isolates belonging to the K. oxytoca group, which includes
the species K. oxytoca, K. michiganensis and K. grimontii, were less often resistant to 4th-generation cephalosporins
than isolates of the K. pneumoniae group, which includes the species K. pneumoniae, K. quasipneumoniae, K. variicola
and “K. quasivariicola” (odds ratio = 0.17, p < 0.001, 95% confidence interval [0.09,0.28]). Within the K. pneumoniae
group, isolates identified as K. pneumoniae were more often resistant to 4th-generation cephalosporins than K.
variicola isolates (odds ratio = 2.61, p = 0.003, 95% confidence interval [1.38,5.06]). K. oxytoca group isolates were
found to be more likely associated with invasive infection to primary sterile sites than K. pneumoniae group isolates
(odds ratio = 2.39, p = 0.0044, 95% confidence interval [1.05,5.53]).
Conclusions: Currently misdiagnosed Klebsiella spp. can be distinguished using a ribosomal marker-based approach
for MALDI-TOF MS. Klebsiella groups and species differed in AMR profiles, and in their association with invasive
infection, highlighting the importance for species identification to enable effective treatment options.
Keywords: MALDI-TOF MS, Klebsiella spp., Invasive infections, Antimicrobial resistance, Species identification

Background
Klebsiella spp. are opportunistic pathogens, resident as respiratory and intestinal microbiota, and are commonly isolated during severe infections such as sepsis, pneumonia
and pyelonephritis [1, 2]. Particularly hypervirulent strains
of K. pneumoniae, which have been linked to specific capsular factors resulting in a muco-viscous phenotype, cause
pyogenic liver abscesses and sepsis [3, 4]. In addition, the
number of multi-drug resistant (MDR) isolates is increasing
globally, carrying plasmids encoding for extended spectrum
beta-lactamase (ESBL) or carbapenemase genes [5, 6]. K.
pneumoniae is part of the ESKAPE pathogens (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter) which were classified by the WHO in 2017 as
critical priority pathogens for research and development of
new antibiotic treatment modalities [7].
The taxonomy of the genus Klebsiella has been in flux
for the past few years, divided into two main groups: the
K. pneumoniae and the K. oxytoca group. Recently, several
new species have been described within the K. pneumoniae group, which includes K. pneumoniae (sensu stricto),
K. quasipneumoniae [8], K. variicola [9], “K. quasivariicola” [10] and K. africana [11]. The K. oxytoca group
comprises K. oxytoca (sensu stricto), K. michiganensis
[12], K. grimontii [13], K. spallanzanii and K. pasteurii
[14]. K. huaxensis [15] is more closely related to the K.
oxytoca group than to the K. pneumoniae group, but
forms a distinct clade (Fig. 1A). Most of the Klebsiella spp.
have been observed within a clinical context [10, 13–17].
The K. oxytoca group has been reported to cause
antibiotic-associated hemorrhagic colitis in neonates, and
hospital-acquired infections such as pneumonia and urinary tract infections (UTI) [18, 19]. Previous studies have

analysed the population structure of a subset of Klebsiella
spp. [10, 20, 21]. The gained knowledge from these studies
could however not yet be translated to clinical routine
diagnostics, and the clinical relevance of these recently described Klebsiella spp. is still unclear.
The newly described Klebsiella spp. are not yet identified with routine hospital-based diagnostic procedures.
Biochemical reaction profiling cannot distinguish between
all Klebsiella spp. [16, 22], neither is 16S rRNA a good sequencing target for species distinction within Enterobacteriaceae [23]. The most widely used technology for
bacterial species identification in microbiological routine
diagnostics is Matrix-Assisted Laser Desorption Ionization
- Time Of Flight Mass Spectrometry (MALDI-TOF MS)
[24]. The two commonly used commercial databases
(MALDI Biotyper (MALDI Biotyper Compass Library, Revision E (Vers. 8.0, 7854 MSP, RUO) Bruker Daltonics,
Bremen, Germany) and VitekMS DB (v.3.2, bioMérieux,
Marcy-l’Étoile, France) allow spectral identification of K.
pneumoniae, K. variicola and K. oxytoca. Importantly, “K.
quasivariicola”, K. quasipneumoniae, K. africana, K.
michiganensis, K. grimontii, K. pasteurii, K. spallanzanii
and K. huaxensis are currently not included in these databases, and strains of these species are wrongly identified
as either K. pneumoniae or K. oxytoca using MALDI-TOF
MS [16]. Fortunately, recent developments show that a
distinction of Klebsiella spp. is possible in routine diagnostics, using Fourier-transform infrared spectrometry [25]
and MALDI-TOF MS using alternative databases [26].
Ribosomal subunit proteins are suitable as phylogenetic protein markers for MALDI-TOF mass spectra, as
they are highly abundant in replicating cells and of relatively low molecular weight [27, 28]. Combinations of
ribosomal subunit protein-derived masses allow the
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Fig. 1 Genomic content of isolates across the Klebsiella genus. A Core-genome phylogeny of the genus Klebsiella including isolates from K. pneumoniae (n =
218), K. quasipneumoniae (n = 83), “K. quasivariicola” (n = 5), K. variicola (n = 109), K. oxytoca (n = 41), K. michiganensis (n = 54), K. grimontii (n = 37) and K.
huaxensis (n = 1) based on 1171 core genes. The species colour key is used throughout the figure and paper. B Pan- (upper) and core- (lower) gene
accumulative curves comparing K. pneumoniae group and K. oxytoca group. C Number of plasmid replicons identified in each isolate, per species. Boxes
indicate the IQR with the median displayed as middle lines. D Plasmid replicons identified by PlasmidFinder in all isolates (n = 548), shown per Klebsiella spp

separation of sub-lineages within Escherichia coli [29]
and Streptococcus agalactiae [30] by MALDI-TOF MS.
The aim of our study was to investigate the clinical
presentation and distribution of AMR and virulence
across the genus Klebsiella. Furthermore, using

whole-genome sequences, we aimed to develop a
ribosomal subunit-based MALDI-TOF MS scheme to
robustly distinguish between Klebsiella spp. in clinical
routine and to apply this on a large international
dataset.

Cuénod et al. Genome Medicine

(2021) 13:150

Methods
An outline of the study method is given in Additional
file 1: Figure S1.
Ethics

Bacterial strains have been collected in clinical routine
diagnostics. The collection of bacterial strains and their
analysis for diagnostic assay development do not fall
under the Swiss human research act, and no ethical approval nor consent to participate from patients was required. The analysis of patient demographic and clinical
outcome data was approved by the “Ethikkommission
Nordwest- und Zentralschweiz” (EKNZ) (BASEC-Nr.
2016-01899 and 2018-00225) for patients who did not
reject the hospitals general research consent. Patients
who did reject the hospital’s general consent were excluded from all analyses which include patient demographic and clinical outcome data.
Bacterial isolates and whole-genome sequencing (WGS)

In total, 261 Klebsiella spp. isolates were collected from
various tissue sources (see Additional file 2: Table S1 for
more details) at three routine diagnostic laboratories in
Switzerland including the University Hospital of Basel
(USB; Basel, Switzerland), Mabritec AG (Riehen,
Switzerland) and Labor Team W AG (LTW; Goldach,
Switzerland)). Isolates were grown on Columbia 5%
Sheep Blood Agar (bioMérieux, Marcy-l’Étoile, France),
and DNA was extracted using the QIACube with the
QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany).
After quality control of the DNA by Tapestation (Agilent, Santa Clara, USA), tagmentation libraries were generated as described by the manufacturer (Nextera XT
kit, Illumina, San Diego, USA). The genomes were sequenced under 24× multiplexing using a 2 × 300 base
pairs V3 reaction kit on an Illumina MiSeq instrument
reaching an average coverage of approximately 60-fold
for all isolates. Eleven isolates, covering reference and
clinical isolates of 6 species were additionally sequenced
on a PacBio Sequel at the Functional Genomics Center
Zurich (FGCZ, ETH Zurich, Switzerland).
All available whole-genome assemblies designated as
Klebsiella spp. were downloaded from NCBI in December 2017 (n = 3047), representing members of the species K. pneumoniae, K. quasipneumoniae, K. variicola,
“K. quasivariicola”, K. oxytoca, K. michiganensis, K. grimontii, K. huaxensis, K. aerogenes and three species of
the genus Raoultella (R. ornithinolytica, R. planticola
and R. terrigena). An additional selection of publicly
available K. pneumoniae whole-genome sequences were
included from NCBI SRA, which was sampled to
maximize diversity (n = 286) [20]. Two sets of Klebsiella
spp. genomes were used for this study: first, a total of n
= 3594 publicly available genome sequences including
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the 3333 described above, and the 261 sequenced at the
USB, were used to in silico predict ribosomal protein
masses. The species identity of these genome sequences
were determined by comparison to the typestrains of K.
pneumoniae, K. quasipneumoniae, K. variicola, “K. quasivariicola”, K. oxytoca, K. michiganensis, K. grimontii, K.
huaxensis R. ornithinolytica, R. planticola and R. terrigena using Average Nucleotide Identity (ANIm) [31] and
a threshold of 96%. Second, a computationally more
manageable subset of these genomes (n = 999) was used
for comparative genomic analyses, selected to represent
the largest genomic diversity between and within species,
and geographically. This subset included all assemblies
of K. quasipneumoniae, K. variicola, “K. quasivariicola”,
K. oxytoca, K. michiganensis, K. grimontii and K. huaxensis. For K. pneumoniae, only strains sequenced at USB
and the previously published, diverse set of sequences
[20] were included. To avoid bias introduced by outbreak strains, we excluded genomes which shared
ANIm values > 99.9% with another genome in the collection, resulting in a final dataset of n = 548 genomes.
Both datasets, including accession numbers and those of
the short and long reads sequenced for this study, can
be found in Additional file 2: Table S1. K. africana, K.
pasteurii and K. spallanzanii were not included in this
analysis as the species were not published at the time of
the analysis and are extremely rare in clinics.

Comparative genomic analysis

WGS data was quality controlled using FastQC [32] and
MetaPhlAn (v2.0) [33] and adaptors were trimmed using
Trimmomatic [34]. Genome assemblies were created
using Unicycler (v0.4.4) [35]. Prokka (1.12) [36] was used
for annotation. Orthologous groups were built using
Roary (v3.10.2, option: -i 90) [37]. The resulting coregenome alignment was used for the construction of a
phylogenetic tree using FastTree (v2.1) [38, 39]. The
sizes of the core- and pan-genomes were calculated
using a python script (https://github.com/
appliedmicrobiologyresearch/Klebsiella-spp) [40].
The O-loci and K-loci were determined using KLEBORATE (v0.3.0) [41–43]. The genomes were investigated
for the presence of known virulence loci (those included
in KLEBORATE and the cytotoxin tilivalline [44]) and
AMR determinants (via KLEBORATE). Potential plasmids were detected by comparing the genomes to the
PlasmidFinder database [45] using abricate [46]. Genomic analyses were performed at sciCORE (http://
scicore.unibas.ch/) scientific computing centre at University of Basel.
Scripts generating figures from the output of these
tools were deposited on Github (https://github.com/
appliedmicrobiologyresearch/Klebsiella-spp) [40].
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In silico prediction of ribosomal subunit protein masses
from WGS data

The molecular weight of 56 ribosomal subunits was predicted in silico as described [26]: Tblastn (v 2.2.31+) was
used to extract the amino acid sequences of 56 ribosomal subunits from 3594 Klebsiella spp. assemblies. Full
ribosomal subunit sequences were retained when start
and stop codons were identified and the length was
within the median ± 3 codons. The subunits L1, L2 and
S12 were not found in over 90% of the genomes and
were therefore excluded from further analysis. The ribosomal subunit protein S1 was also excluded because S1like domains are found in proteins unrelated to the ribosome [41]. The masses of the ribosomal subunit protein
alleles were predicted including the N-end rule to account for possible methionine loss at the N-terminus
[47]. The mass of subunit L33 was corrected by 15 Da to
account for post translational methylation [48].
Definition of species-specific MALDI-TOF MS marker
masses

A diverse selection of bacterial isolates (n = 50) representing at least eight isolates of K. pneumoniae, K. variicola, K. oxytoca, K. michiganensis and K. grimontii,
whole-genome sequenced for this study, were used to
validate the detection of the predicted marker masses in
MALDI-TOF mass spectra. These represent the most
common species within the K. pneumoniae and the K.
oxytoca group [5, 20, 21]. MALDI-TOF mass spectra of
these 50 Klebsiella isolates were acquired on four
MALDI-TOF MS systems in different laboratories, including one microflex Biotyper (Bruker Daltonics, Bremen, Germany) at the USB (Basel, Switzerland), one
Axima Confidence (Shimadzu, Ngoyo, Japan) at Mabritec AG (Riehen, Switzerland) and two VitekMS devices
(bioMérieux, Marcy-l’Étoile, France) at the Laborgemeinschaft 1 (LG1) (Zürich, Switzerland) and the Ente
Ospedaliero Cantonale (Bellinzona, Switzerland). The
Klebsiella isolates were measured on each system in
quadruplicate using direct smear method and overlaid
with formic acid (70% for the spectra acquired on the
Microflex Biotyper and 25% for all other machines) and
cyano-4-hydroxycinnamic acid (CHCA) matrix solution.
MALDI-TOF mass spectra acquired on the VitekMS
(bioMérieux, Marcy-l’Étoile, France) (n = 400 spectra)
were output as .mzml files containing a list of peaks per
spectrum. For MALDI-TOF mass spectra acquired on
the Axima Confidence (n = 200 spectra) peak picking
was performed using the Launchpad Software (v2.8, Shimadzu, Ngoyo, Japan) (parameters: scenario: “Advanced”; peak width: 80 chans; smoothing method:
“Average”; smoothing filter width: 500 chans; peak detection method: “Threshold-Apex”; threshold type: “dynamic”; threshold offset: 0.025 mV; threshold response
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1.25×). MALDI-TOF mass spectra acquired on a microflex Biotyper (n = 200 spectra) were output as fid-files
and peak picking was performed in the flexAnalyses
software (v3.4) (parameters: peak detection: “Centroid”;
signal to noise threshold: 2; relative intensity threshold:
0%; minimal intensity threshold: 600; maximal number
of peaks: 300; peak width: 4 m/z; peak height: 90%; baseline subtraction: “TopHat”; smoothing algorithm:
“Savitzky Golay”; smoothing width: 2 m/z; smoothing cycles: 10). All MALDI-TOF mass spectra were internally
calibrated with the conserved masses 4365.3 m/z, 6383.5
m/z, 7158.7 m/z, 7244.5 m/z, 10,286.1 m/z and a tolerance range of 1000 ppm, using the R-packages MALDIQuant and MALDIQuantForeign [49]. All spectra were
exported in ASCII format and interrogated for the ribosomal subunit protein allele masses predicted from the
respective WGS data. We used the following criteria to
select the ribosomal target proteins for subsequent species identification, in order to maximize discriminatory
power and reproducibility: ribosomal subunit protein
masses in the mass range from 3000–13,000 Da (L36,
S22, L34, L30, L32, L33, L35, L29, L31, S21, L27, S20,
S15, S19, L25, S14, L21, L18) were selected if they were
detected with a reproducibility > 80% in a least one
centre, with the exception of ribosomal subunit L28,
which had a maximal reproducibility of 57%. Additionally, ribosomal subunit protein masses in the higher
mass range from 13,000 to 15,000 Da (L19, S13, L20, S8,
L17, S9) were included, as they were detected with a reproducibility of at least 35% in at least one centre. Ribosomal subunits with a predicted molecular weight >
15,000 Da were not included for further analysis.
The bacterial species was assigned for which most
marker masses could be detected in the acquired mass
spectrum. If in a spectrum an equal number of marker
masses from different Klebsiella species were found, the
spectrum was assigned a multi-species ID (e.g. K. michiganensis / K. oxytoca) and labelled as “Multispecies ID
only”.
Classification of MALDI-TOF mass spectra acquired in
routine microbiology diagnostics

Routinely acquired MALDI-TOF mass spectra (n =
33,160) from eight international healthcare institutions
from four countries were analysed: the Soroka Medical
Centre (SMC; Beer Sheva, Israel); the Hospital General
Universitario Gregorio Marañón (HGUM; Madrid,
Spain); the Servizio di microbiologia EOLAB, Ente Ospedaliero Cantonale (Bellinzona, Switzerland); the LG1,
(Zurich, Switzerland); the LTW (Goldach, Switzerland);
the USB (Basel, Switzerland); the Maastricht University
Medical Center (MUM; Maastricht, the Netherlands)
and the University Medical Center Groningen (UMCG;
Groningen, the Netherlands). The MALDI-TOF mass
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spectra were processed as described above. Each routinely acquired spectrum was interrogated for the presence of the reproducibly detected ribosomal protein
subunit derived mass combinations, with an accepted
error range of 300 ppm. In total, 10,814 MALDI-TOF
mass spectra were from duplicated bacterial isolates and
excluded from further analysis, leading to a final number
of 22,346 MALDI-TOF mass spectra representing
unique bacterial isolates.
Phenotypic profiling

The same collection of Klebsiella spp. strains (n = 50),
which were used to define species-specific marker
masses, were subjected to biochemical profiling on a
Vitek2 (bioMérieux, Marcy-l’Étoile, France) using the
GN ID card and the API50ch panel (bioMérieux, Marcyl’Étoile, France). Primary metabolites of the same strains
were measured and analysed as described in Additional
file 3: Supplementary Methods. Additionally, 11 strains
were subject to fatty acid profiling as described in Additional file 3: Supplementary Methods. These 11 strains
included reference strains of the species K. pneumoniae,
K. quasipneumoniae, K. variicola, K. oxytoca and K.
michiganensis, one clinical isolate for each of the species
K. pneumoniae, K. variicola, K. oxytoca and K. michiganensis and two clinical isolates of the species K.
grimontii.
Antimicrobial resistance determination

AMR profiles of isolates associated with the retrospectively analysed spectra were accessed through the laboratory information systems of the USB and the LTW (n =
7876). The accessed AMR profiles were measured in
clinical routine diagnostics from January 2015 to June
2018 using either microdilution methods (Vitek2, ASTN242 GN Cards, bioMérieux), MIC strip tests (Liofilchem, Roseto degli Abruzzi, Italy) or disc diffusion tests
(ThermoFisher Scientific, Waltham, USA). Breakpoints
were interpreted as susceptible or resistant according to
the current EUCAST Breakpoint table (v6.0 – 8.1) [50].
Retrospective assessment and statistical analysis of
clinical data

We assessed the relative distribution of Klebsiella spp.
with regard to laboratory and country of isolation (n =
22,346, including spectra from eight laboratories). We
examined the association of Klebsiella groups and species with resistance to antibiotic classes using logistic regression (post hoc analyses; n = 7876, including spectra
from two laboratories).
Patient demographic and clinical data from patients
with Klebsiella spp. infections were retrospectively
accessed via the USB clinical information system in a
case report form for a subset of clinical cases (n = 957).
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Inclusion criteria were as follows: patients for which at
least one isolated bacterial colony was identified as Klebsiella spp. by MALDI-TOF MS collected between January 2015 and June 2018 at the USB and who did not
reject the hospital’s general research consent form, as
approved by the ethical committee. The USB is a tertiary
healthcare centre with more than 750 beds in a low endemic region for ESBL-producing bacteria [51].
The clinical outcomes of 957 patients with Klebsiella
infections were analysed and included all-cause mortality
within 30 days from Klebsiella spp. diagnosis as primary
endpoint and secondary endpoints: (i) time to death
after Klebsiella spp. diagnosis in days, (ii) admission to
an intensive care unit (ICU), (iii) invasive infection to
sterile sites (including the bloodstream, deep tissues and
cerebrospinal fluids), (iv) length of hospital stay in days,
(v) the number of medical disciplines involved to manage the specific case (as a surrogate marker for case
complexity) and (vi) whether the infection was mentioned in the patient letters. Clinical outcomes were examined for an association with distinct Klebsiella spp.,
age, sex, immunosuppression (defined as a dose equivalent of 20 mg prednisone / day or mentioning of immunosuppression in the patient notes), Charlson
Comorbidity Index (CCI) [52], resistance to 3rdgeneration cephalosporins and antibiotic treatment (defined as at least one dose of antimicrobial agent at hospital entry or during the hospital stay). Binary outcomes
were analysed using generalized linear mixed models
(GLMM) with binomial error distribution. Count outcomes (number of medical disciplines involved) were
analysed using GLMM with Poisson error distribution.
Time to death within hospital and length of hospital stay
(time to discharge) were considered competing risks and
jointly analysed by a competing risks model. For further
detail, see Additional file 3: Supplementary Methods.

Results
Comparative genomic analyses of Klebsiella spp.

To determine the core-genome of the genus Klebsiella,
from the 3594 Klebsiella spp. isolates with available
WGS, a selection of 548 isolates was made, reflecting between- and within-species diversity. The genus coregenome comprises n = 1171 genes, which are genes
shared between 99% of these 548 isolates. The coregenome-based phylogeny (Fig. 1A) clearly shows the
Klebsiella phylogeny as previously described [5, 20, 21],
with subspecies within K. quasipneumoniae (K. quasipneumoniae subsp. quasipneumoniae and K. quasipneumoniae subsp. similipneumoniae) as well as within K.
variicola (K. variicola subsp. variicola and K. variicola
subsp. tropica) which can be distinguished. These species also contain a diverse array of strains, in contrast to
K. pneumoniae, which is more homogeneous when
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comparing these 1171 core genes. Interestingly, K. grimontii includes two deeply branching sub clades, which
have not yet been described as subspecies (Fig. 1A).
The pan-genomes of the K. pneumoniae group and the
K. oxytoca group were determined by investigating the
number of unique orthologous clusters within our genome data set (Fig. 1B). A larger pan- to core-genome ratio could suggest adaptation to diverse environments,
whereas a smaller pan- to core-genome ratio could, in a
clinical context, reflect adaptation to the human host or
even site-specific infections. Both groups show an open
pan-genome, with the number of unique orthologous
clusters increasing as more genomes are added to the
analysis. There seems to be a larger increase in the pangenome of the K. oxytoca group with strains added, although fewer genomes have been sampled to date. At a
species level, pan-genome sizes of those within the K.
pneumoniae group are relatively similar, whereas K.
michiganensis within the K. oxytoca group shows a larger
pan-genome, although this may reflect sampling bias
(Additional file 1: Figure S2).
Plasmid complements are known to vary widely between Klebsiella isolates and can carry accessory genes
involved in AMR and pathogenicity [53–55]. We detected a lower median number of plasmid replicons per
isolate within the K. oxytoca group (median = 2, interquartile range (IQR) = 0–4) compared to isolates of the
K. pneumoniae group (median = 4, IQR = 2-4) (Fig. 1C).
The lowest median number of plasmids was detected for
K. grimontii isolates (median = 1, IQR = 0–5), and the
highest median number of plasmids detected in “K. quasivariicola” (median = 7, IQR = 5–10) isolates. We also
observed that within the K. pneumoniae group, the median count of plasmids detected was lower in K. variicola isolates (median = 3, IQR = 0–5) than in isolates of
the other species of the K. pneumoniae group (median =
4, IQR = 3–6 for K. pneumoniae; median = 5, IQR = 2–
7 for K. quasipneumoniae and median = 7, IQR = 5–10
for “K. quasivariicola”) (Fig. 1C). No group specificity
could be detected in plasmid replicon profiles (Fig. 1D).
The two replicons known to be particularly related to
virulence, plasmids KpVP-1 and KpVP-2, (IncHI1B_
pNDM-MAR and IncFIB(K)_Kpn3 respectively), were
detected in isolates from all Klebsiella spp. (K. pneumoniae n = 162/218, 73.3%; K. quasipneumoniae n = 61/83,
73.5%; K. variicola n = 56/109, 51.4%; “K. quasivariicola”
n = 4/5, 80.0%; K. oxytoca n = 18/41, 43.9%; K. michiganensis n = 23/54, 42.6%; K. grimontii n = 16/37, 43.2%)
with the exception of K. huaxensis, for which only a single genome was available for this study.
From long read genome assemblies for a subset of 11
isolates sequenced as part of this study, the plasmids assembled for nine isolates agreed with the replicon findings. In K. quasipneumoniae DSM-2811T, we detected a
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plasmid of 4267 bp with 99.1% identity and 71% coverage to the K. pneumoniae plasmid pB1019, which was
not identified by PlasmidFinder. A previously undescribed plasmid of 3596 base pairs was identified within
K. grimontii 606641-17, which does not carry any known
virulence or resistance factors, showing that there is further diversity of Klebsiella spp. plasmids to discover.
Virulence factors of Klebsiella spp.

Virulence factors were investigated by comparing 548
Klebsiella spp. genomes against known databases and
virulence factors. Genes encoding the iron-chelating
siderophores aerobactin and salmochelin were detected
in a minority of isolates (n = 18/548, 3.3% and n = 21/
548, 3.8% of isolates, respectively), only within K. pneumoniae and K. quasipneumoniae, often co-occurring
within isolates. The siderophore yersiniabactin is more
prevalent in isolates of the K. oxytoca group (n = 111/
132, 84.1%) than in the K. pneumoniae group (n = 52/
415, 12.5%). The kfu operon, encoding an iron transport
system, was detected in isolates of all species except K.
oxytoca (n = 333/548; 60.8% of all isolates and n = 0/41;
0% within the species K. oxytoca).
The genes involved in allantoin metabolism, which enable Klebsiella spp. to assimilate nitrogen from this
metabolic intermediate and increase its virulence in certain infection sites, were detected in isolates of all species (n = 132/548; 24.1%), notably in all K. oxytoca (n =
41/41; 100%) and K. grimontii (n = 37/37; 100%) isolates.
The distribution of bacterial toxin operons encoding
microcin, colibactin and tilivalline was also examined.
The complete microcin operon was detected in a few K.
pneumoniae genomes (n = 8/218; 3.7%) and in one K.
michiganensis genome (n = 1/54; 1.9%), whereas colibactin was detected solely in K. pneumoniae (n = 11/218;
5.0%). In contrast, the complete tilivalline operon was
exclusively identified in isolates within the K. oxytoca
group (n = 64/132; 48.5%) particularly in isolates of K.
oxytoca (n = 29/41; 59.2%) and K. grimontii (n = 30/37;
81.1%) (Fig. 2A).
The regulator of the mucoid phenotype rmp genes
were detected in K. pneumoniae (n = 14/218; 6.4%) and
K. quasipneumoniae (n = 1/83; 1.2%). Ecotin has been
described as being able to modulate the host immune response [56] and was detected in isolates belonging to all
species (n = 445/548; 81.2%).
We found a high diversity of K-loci in our dataset,
with 114 capsule types. KL107 was found to be the most
prevalent K-locus type across all Klebsiella spp. (107/
548; 19.5%), with the exception of K. huaxensis where
only one genome was included (KL46; Fig. 2B). KL1 and
KL2, which are associated with a muco-viscous phenotype and frequently detected in hypervirulent strains,
were exclusively detected in isolates of species within
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Fig. 2 Virulence factors across the genus Klebsiella. A Core-genome phylogeny of 548 Klebsiella spp. genomes (left, in line with Fig. 1A) with
identified virulence-related genes shown per isolate (right), coloured by species. B Polysaccharide (K-locus, left) and lipopolysaccharide (O-locus,
right) predicted serotypes of isolates grouped by species

the K. pneumoniae group; KL1 was detected in isolates
of K. pneumoniae (n = 4/218; 1.8%) and K. quasipneumoniae (n = 4/83; 4.8%), whereas KL2 was detected in
isolates of K. pneumoniae (n = 10/218; 4.6%) and K. variicola (n = 1/109; 0.9%). Within the O-loci, we found
less diversity, with 17 types. Type O1v1 is the most common in isolates of K. pneumoniae (n = 53/218, 24.3%),
K. michiganensis (n = 41/54; 75.9%) and K. grimontii (n
= 36/37; 97.2%), whereas most isolates of K. oxytoca (n
= 22/41; 53.7%) carry the O-locus OL104. The most
common combination of K- and O-loci per species were
as follows: KL107-O2v1, KL107-OL101 and KL64-O1v1
in K. pneumoniae (each 7/218; 3.2%), KL48-O5 in K.
quasipneumoniae (n = 4/83; 4.8%) and KL107-O5 in K.
variicola (n = 6/109; 5.5%). All five “K. quasivariicola”
genomes studied carry unique combinations of K- and
O-loci. Within the K. oxytoca group, the most common
combination of K- and O-loci is carried by a bigger proportion of the isolates compared to the K. pneumoniae
group species: KL68-O5 in K. oxytoca (n = 7/41; 17.1%),

KL107-O1v1 in K. michiganensis (n = 11/54; 20.4%) and
K. grimontii (n = 14/37; 41.2%) were the most frequently
detected combinations.
Antimicrobial resistance genes in Klebsiella spp.

We examined the occurrence of AMR genes in Klebsiella spp. (n = 548) (Additional file 1: Figure S3). We detected the chromosomally encoded AmpH for strains of
the K. pneumoniae group and a beta-lactamase of the
LEN family in K. variicola isolates, which both confer
low-level resistance to beta-lactam antibiotics [57]. Further, we detected the chromosomally encoded betalactamase genes blaOXY1-blaOXY8 in genomes within the
K. oxytoca group, for which each species carries distinct
variants, as described [58].
Fewer isolates of the K. oxytoca group were found to
carry ESBL genes (8/132; 6.1%) than isolates of the K.
pneumoniae group (125/415; 30.1%). Within the K.
pneumoniae group, fewer isolates of the species K. variicola were found to carry ESBL genes (14/109; 12.8%),
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compared to isolates within K. pneumoniae (78/218;
35.8%), K. quasipneumoniae (32/83; 38.6%) and “K. quasivariicola” (1/5; 20.0%). We observed a higher number
of K. quasipneumoniae isolates encoding carbapenemases (12/83; 14.4%) compared to K. pneumoniae (15/
218; 6.9%), K. variicola (9/109; 8.6%) and “K. quasivariicola” (0/5; 0%). Within the K. oxytoca group, we detected the highest frequency of ESBL and
carbapenemases in K. michiganensis (6/54; 11.1% and 5/
54; 9.3%, respectively) compared to K. oxytoca (both in
1/41; 2.4%) and K. grimontii (both in 2/37; 5.4%).
Klebsiella spp. identification in routine diagnostics

Given the group- and species-specific trends in accessory
genome composition and content, an accurate species
identification may have an important clinical impact. For
the strains included in this study, fatty acid analysis, GCMS and a panel of biochemical reactions were unable to
identify a characteristic feature that could be used to distinguish unambiguously between the included Klebsiella
spp. (Additional file 4: Table S2, Additional file 1: Figure
S4, Additional file 5: Table S3). As such, in order to find
a robust and accurate way to distinguish Klebsiella spp.
based on MALDI-TOF mass spectra, we used ribosomal
subunit proteins as species-specific MALDI-TOF MS
markers. To do this, we first in silico-predicted protein
masses of the 56 ribosomal subunit proteins from 3594
genome drafts.
Only proteins with a mass between 2000 and 20,000
Da can be detected in MALDI-TOF mass spectra, and
due to the intrinsic measurement error of MALDI-TOF
MS, not all predicted masses can be distinguished. Additionally, not all ribosomal subunit proteins can be
equally ionized, and therefore detected, in similar proportions. Therefore, to determine the practical value of
our approach, we examined which of these potential
marker masses can reproducibly be detected in MALDITOF mass spectra of routine quality. Fifty isolates, representing the species K. pneumoniae (n = 10), K. variicola
(n = 10), K. oxytoca (n = 8), K. michiganensis (n = 12)
and K. grimontii (n = 10), all with species identification
confirmed by WGS, were analysed in quadruplicate on
four different MALDI-TOF MS systems in different laboratories, resulting in the generation of 800 spectra.
The 25 ribosomal subunits L17, L18, L19, L20, L21, L25,
L27, L28, L29, L30, L31, L32, L33 (methylated), L34,
L35, L36, S8, S9, S14, S13, S15, S19, S20, S21 and S22
were subsequently included as valid target proteins for
identification of Klebsiella spp. The reproducibility of
these marker masses varied between the different laboratories (Additional file 6: Table S4). We found a complete
set of these 25 target proteins in 3360 assemblies and
therefore based our further analyses on these predicted
mass profiles (Additional file 7: Table S5).
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We assessed the distribution of the in silico-predicted
masses of these target proteins in a representative dataset of 464 genomes, comprising those which were included in the comparative genomic analysis and were
complete for these 25 target proteins. We identified
multiple group- and species-specific alleles for K. pneumoniae, K. variicola, “K. quasivariicola”, K. oxytoca and
K. grimontii (Fig. 3). No marker mass uniquely identifying K. michiganensis and K. quasipneumoniae was detected. In order to unambiguously separate K.
michiganensis and K. quasipneumoniae from closely related species, a combination of marker masses needs to
be detected (e.g. S15 at 10,078 Da and L25 at 10,636 Da
for K. michiganensis, Fig. 3).
Based on the differential masses of the 25 target proteins, we can distinguish 110 distinct Klebsiella spp.
ribosomal mass profiles (Additional file 8: Table S6) that
allow us to distinguish K. pneumoniae, K. quasipneumoniae, K. variicola, "K. quasivariicola", K. oxytoca, K.
michiganensis, K. grimontii and K. huaxensis. These 110
distinct ribosomal mass profiles were subsequently included in an in house developed reference database for
species identification. We assessed the specificity and
sensitivity of this approach, using the spectra (n = 800)
of the same diverse Klebsiella spp. isolates (n = 50). The
species identification by MALDI-TOF MS was compared
to the species identity as assigned by WGS of the identical isolate. If essential target proteins could not be detected in a MALDI-TOF mass spectrum and the
acquired mass profile did not allow unique species identification, this spectrum was labelled as “Multispecies ID
only”. Table 1 shows the evaluation of the species identification of these spectra, resulting from comparison of the
acquired MALDI-TOF mass spectra with the 110 ribosomal marker mass profiles. The identification was evaluated
on two levels: (i) whether the assignment to K. pneumoniae or K. oxytoca group was correct and (ii) whether the
correct species within each group could be assigned. Species identification using these marker mass profiles resulted generally in accurate identification and provided
better species identification within the K. oxytoca group
than the currently used commercially available databases
Microflex Biotyper Database (MALDI Biotyper Compass
Library,Revision E (Vers. 8.0, 7854 MSP, RUO) ) and the
VitekMS Database (v.3), as these databases do not include
K. grimontii and K. michiganensis.
The sensitivity and specificity of the approach (Table
1) were computed based on the identification of
MALDI-TOF mass spectra acquired on all four MALDITOF MS systems. Specificity and sensitivity on group
level were > 98% using marker mass profiles, for all
tested species on all four MALDI-TOF MS systems,
reflecting a low probability of false positive results using
this approach.
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Fig. 3 Distribution of the in silico-predicted masses of 25 target proteins encoded by the species K. pneumoniae (n = 208), K. quasipneumoniae (n
= 60), K. variicola (n = 68), “K. quasivariicola” (n = 3), K. oxytoca (n = 37), K. michiganensis (n = 51), K. grimontii (n = 36) and K. huaxensis (n = 1)

Sensitivity on the species level varied between the
MALDI-TOF MS systems, especially within the K. oxytoca group. For the species K. oxytoca, sensitivity at the
species level ranged from 37.5 to 100% between the four
MALDI-TOF MS systems, for K. michiganensis from 8.3
to 70.8% and for K. grimontii from 12.5 to 95.0%. Species
identification within the K. oxytoca group requires the
detection of marker masses in a high mass range and
variations in sensitivity between the MALDI-TOF MS
systems could potentially be linked to MALDI-TOF
mass spectral quality [59].
Classification of international routinely acquired MALDITOF mass spectra

Using the 110 species-specific marker mass profiles, we
retrospectively analysed 22,346 spectra derived from
bacterial isolates from eight healthcare centres in four
countries (dataset (a), Additional file 1: Figures S1 and
S5). All spectra had previously been used to diagnose
isolates as Klebsiella spp. in routine diagnostic laboratories. Re-analysing the spectra using the newly compiled
mass profile database, we attempted to categorize all
spectra first into the two groups and then to one of the
eight species in the database (Fig. 4A, B).

A subset of the samples (n = 427; 1.9%) were identified
as Raoultella spp. or K. aerogenes and excluded from
further analysis. In total, 85 samples (0.3%) could only
be identified to the genus level. The remaining 21,834
samples (97.7%) were categorized as K. pneumoniae
group or K. oxytoca group. Of these, a higher proportion
of samples could be categorized to the species level
within the K. pneumoniae group (n = 14,867/17,555;
84.7%), than within the K. oxytoca group (n = 2718/
4249; 64.0%), which reflects the difficulty to reproducibly
detect all required species-specific marker masses in the
K. oxytoca group. The proportion of samples which
could not be categorized to the species level varied by
healthcare centre and MALDI-TOF MS system and
ranged from 9.8% (n = 40/407 samples) to 30.5% (n =
439/1440 samples) within the K. pneumoniae group and
from 22.8% (n = 349/2560 samples) to 84.8% (n = 217/
256 samples) within the K. oxytoca group. The
remaining 17,585 samples (78.69%) could unambiguously be identified to the species level. Of these, across
all centres, we identified: K. pneumoniae (n = 12,523;
71.2%), K. quasipneumoniae (n = 575; 3.3%) K. variicola
(n = 1717; 9.8%), “K. quasivariicola” (n = 52; 0.3%), K.
oxytoca (n = 1445; 8.2%), K. michiganensis (n = 836;

Table 1 Evaluation of the species identification of 50 Klebsiella spp. isolates by MALDI-TOF mass spectra using ribosomal marker
mass profiles. Species identification of 800 MALDI-TOF mass spectra using 110 marker mass profiles was compared to the species
identification assigned using WGS data. Specificity and sensitivity were computed on two levels: (i) whether the assignment to K.
pneumoniae group or K. oxytoca group was correct (= “Group level”) and (ii) whether the correct species within each group could
be assigned (= “Species level”)
Species identification by WGS Identification of MALDI-TOF mass spectra using Marker Mass profiles based on 25 pre-defined ribosomal
subunit proteins
Group level

Species level

Sensitivity [%]

Specificity [%]

Sensitivity [%]

Specificity [%]

K. pneumoniae

98.8

100

70.0

100

K. variicola

98.1

100

93.1

100

K. oxytoca

99.2

100

80.5

99.4

K. michiganensis

100

100

44.3

100

K. grimontii

99.4

100

70.6

100
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Fig. 4 Occurrence of Klebsiella spp. in clinical settings, as determined by ribosomal marker MALDI-TOF MS method. A Occurrence of Klebsiella
groups and species in eight healthcare centres from Israel (n = 1), Spain (n = 1), Switzerland (n = 4) and the Netherlands (n = 2), sorted by
increasing occurrence of the K. oxytoca group. B Occurrence of Klebsiella groups and species in patient samples from various isolation sites.
“Primary sterile sites” includes deep wounds, aspirates and deep tissues; “Respiratory tract” includes sputum, bronchoalveolar lavage and tracheal
secretion; “Superficial swabs” includes swabs from superficial wounds and skin infections. C Antibiotic resistance of Klebsiella spp. (BENI = beta
lactams with beta-lactamase inhibitors, CEF3 = 3rd-generation cephalosporins, CEF4 = 4th-generation cephalosporins, AGLY = aminoglycosides,
CARBA = carbapenems, CHIN = quinolones, PMX = polymyxins). Please note that the colour grading is on log-scale

4.8%), K. grimontii (n = 425; 2.4%) and K. huaxensis (n =
12; 0.1%).
Interestingly, we observed different frequencies of the
two Klebsiella groups and species depending on the originating healthcare centre, possibly reflecting a geographical trend of pathogenic Klebsiella spp. distribution (Fig.
4A): The proportion of isolates belonging to the K.

oxytoca group was higher in more northern regions, a
finding which requires further investigation. The proportion of Klebsiella groups and species was also found to
vary depending on the patient material from which it was
isolated (Fig. 4B). Isolates of the K. oxytoca group were
least abundant in urinary tract samples and most abundant in samples of the gastro-intestinal tract samples.
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AMR profiles

Information on phenotypic AMR and isolation source
was available for 7876 samples from two healthcare centres in Switzerland (USB and LTW), (dataset (b), Fig.
4C, Additional file 1: Figures S1 and S5) for which spectra had been analysed. Isolates of the K. oxytoca group
were more likely to be resistant against penicillins including beta-lactamase inhibitors and 3rd-generation
cephalosporins (OR 2.79, p < 0.001, 95% CI [1.70, 4.63];
OR 2.45, p = 0.005, 95% CI [1.31, 4.58], respectively) but
less often resistant to 4th-generation cephalosporins and
aminoglycosides (OR 0.17, p < 0.001, 95% CI [0.09,
0.28]; OR 0.22, p < 0.001, 95% CI [0.12, 0.35]) than isolates of the K. pneumoniae group (Additional file 9: Tables S7 - S9). Within the K. oxytoca group we found K.
oxytoca to be less resistant to penicillins including betalactamase inhibitors, than K. michiganensis (OR 0.57, p
< 0.001, 95% CI [0.42, 0.75]) (Additional file 9: Table S7).
Within the K. pneumoniae group, isolates identified as
K. pneumoniae were more resistant to penicillins including beta-lactamase inhibitors, 3rd- and 4th-generation
cephalosporins as well as to aminoglycosides than K.
variicola (OR 2.11, p < 0.001, 95% CI [1.42, 3.18]; OR
2.61, p < 0.003, 95% CI [1.38,5.06] and OR 5.80, p <
0.001, 95% CI [2.40,20.04], respectively) (Additional file
9: Tables S8-S10).

Clinical endpoints

Data from patient charts of 957 clinical cases at the USB
were reviewed and analysed on multiple clinical endpoints (dataset (c), Additional file 1: Figures S1 and S5).
In order to examine the clinical phenotype of the Klebsiella groups and species, independent of their AMR burden, we corrected our model for resistance against 3rdgeneration cephalosporins, which is associated with production of ESBL. Clinical outcomes and explanatory
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variables are summarized in Additional file 10: Tables
S11-S12.
We found no evidence for Klebsiella group- or
species-specific association with our primary 30-day
mortality endpoint (Additional file 10: Table S13). As a
general finding, female patients seemed to have better
outcomes than male patients: all-cause 30-day mortality
was less likely for female patients (OR 0.60, p = 0.012,
95% CI [0.40, 0.89]), female patients were less likely to
be affected by invasive infection of sterile sites (OR 0.54,
p = 0.002, 95 % CI [0.37, 0.79]) and to be admitted to an
ICU (OR 0.63, p = 0.009, 95 % CI [0.45, 0.89]) (Table 2,
Additional file 10: Tables S13 - S14). Furthermore, increasing CCI and increasing age seemed to be associated
with higher 30-day mortality (OR 1.16, p = 0.40, 95% CI
[1.01,1.34], and OR 1.36, p < 0.001, 95% CI [1.24,1.49],
respectively), whereas antibiotic treatment at entry or
during hospitalization was associated with higher odds
for ICU admission (OR 4.41, p < 0.001 and 95% CI
[2.10,8.93]) (Tables S15 – S16).
Strikingly, isolates of the K. oxytoca group were more
likely to be involved in invasive infection compared to
isolates of the K. pneumoniae group (OR 2.39, p = 0.044,
95% CI [1.05,5.53]). As we corrected in our model for
resistance against 3rd-generation cephalosporins, and as
the K. oxytoca group is not associated with a higher burden of AMR, we hypothesize that this increased association to invasive infections is independent of AMR and
might reflect increased virulence of this group.
We found no evidence for Klebsiella group- or
species-specific associations with the remaining clinical
outcomes (Additional file 10: Tables S14 – S17).

Discussion
We have described a MALDI-TOF MS method allowing
the identification of clinically important and currently
often misdiagnosed Klebsiella spp. and applied it to an

Table 2 Odds ratio estimates for invasive infection using the generalized linear mixed-effects model (GLMM). n = 732 complete
observations with 162 events. OR = odds ratio; CI = confidence interval; CCI = Charlson Comorbidity Index
OR

95 % CI

Z

p value

K. oxytocagroupvs. K. pneumoniaegroup

2.39

[1.05,5.53]

2.01

0.044

K. oxytocavs.K. michiganensis

0.75

[0.42,1.34]

− 0.97

0.33

K. oxytoca vs. K. grimontii

0.64

[0.30,1.36]

− 1.15

0.252

K. pneumoniae vs. K. variicola

1.08

[0.69,1.65]

0.35

0.724

K. pneumoniae vs. K. quasipneumoniae

0.64

[0.35,1.15]

− 1.44

0.149

CCI

1.14

[1.04,1.25]

2.95

0.003

Age (centred, 10 years increase)

0.84

[0.75,0.95]

− 2.78

0.005

Female (ratio)

0.54

[0.37,0.79]

− 3.17

0.002

Immunosuppression

0.5

[0.29,0.86]

− 2.5

0.012

Resistance to 3rd-generation cephalosporins

1.31

[0.44,3.74]

0.5

0.618

Antibiotic treatment at entry or during hospitalization

3.11

[1.44,6.49]

2.92

0.003
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international dataset of over 22,000 unique bacterial isolates from microbiological routine laboratories. While
species-specific MALDI-TOF MS patterns within the
genus Klebsiella have previously been described [8, 25,
60], their discriminatory power has not yet been assessed
in large routinely acquired mass spectral datasets.
Using our ribosomal marker-based approach, we are
able to separate eight species of the genus Klebsiella: K.
pneumoniae, K. quasipneumoniae, K. variicola, “K. quasivariicola”, K. oxytoca, K. michiganensis, K. grimontii
and K. huaxensis. This higher phylogenetic resolution
power represents an important step forward in clinical
diagnostics as “K. quasivariicola”, K. michiganensis, K.
grimontii and K. huaxensis are currently not found in
commonly used databases. Mass spectral quality plays
an important role in distinguishing the species within
the K. oxytoca group, as the species-specific peaks lie in
a high mass range with m/z values above 10,000. Moreover, in order to unambiguously identify the species K.
michiganensis, a unique combination of marker masses
in a higher mass range needs to be detected, posing an
additional challenge for identification. The inability to
detect these in many spectra decreases sensitivity. We
evaluated our approach by computing sensitivity and
specificity values for five clinically important Klebsiella
spp.. A limitation of the current study is that the most
recently described Klebsiella spp., K. africana, K. pasteurii and K. spallanzanii were not included in the analysis. Identifying species-specific marker masses for
these, and a similar evaluation for the less frequently observed Klebsiella species would be desirable in future. A
recent study introduced a web-based tool which uses
other core proteins than ribosomal subunit proteins to
distinguish between the Klebsiella spp. [26]. Combining
these and our ribosomal marker masses could potentially
increase the resolution of MALDI-TOF mass spectral
identification, even below the species level.
Marker-based approaches are independent of the
MALDI-TOF MS system used. Therefore, we were able to
assess the occurrence and clinical phenotype of important
Klebsiella spp. in international clinical laboratories using
MALDI-TOF MS systems from different manufacturers.
While K. pneumoniae remains the most commonly detected species, we also detected isolates from each of the
species, which are currently not routinely identified by
common MALDI-TOF MS databases, including K. quasipneumoniae, “K. quasivariicola”, K. michiganensis, K. grimontii and K. huaxensis from a variety of patient material.
Our data provide evidence that infections with isolates of
the K. oxytoca group were more likely to be invasive than
infections with isolates of the K. pneumonia group,
highlighting the clinical importance of this underappreciated group. The clinical cases analysed in this study
were treated at the same healthcare centre in a low
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endemic region for ESBL-producing bacteria. Further studies from different regions would be needed in order to confirm these results in other epidemiological backgrounds.
Due to the higher prevalence of the K. pneumoniae
group infections, a larger absolute number of invasive
infections are caused by isolates of the K. pneumoniae
group than by isolates of the K. oxytoca group. Thus, infections with a K. oxytoca group isolate tend to be less
frequent, but more severe, a finding which could potentially be linked to the increased frequency of certain
virulence factors, such as the siderophore yersiniabactin,
genes involved in allantoin metabolism and the cytotoxin tilivallin. Yersiniabactin and genes involved in the
allantoin metabolism are well established virulence factors of K. pneumoniae [61, 62], and their frequent occurrence in assemblies of the K. oxytoca group has been
observed before [21, 63]. Based on the data acquired in
this study, we describe an indirect link between the association of K. oxytoca group strains and invasive infection
and the occurrence of these virulence factors in genomes
of the same species. However, in order to assess whether
these factors actually increase the virulence of K. oxytoca
group strains, functional studies are needed.
Bloodstream infections caused by K. variicola have
been described as causing a higher mortality than bloodstream infections caused by K. pneumoniae [64], a finding that we could not confirm in our dataset.
Resistance to 3rd-generation cephalosporins is most
often conferred by ESBLs, which were enriched in the
analysed genomes of K. pneumoniae group compared to
the K. oxytoca group (Additional file 1: Figure S3).
Within the K. pneumoniae group isolates for which
spectra were analysed, we observed a higher proportion
of isolates resistant to 3rd- and 4th-generation cephalosporins and aminoglycosides in K. pneumoniae compared to K. variicola. The lower proportion of resistant
isolates within K. variicola has previously been described
[65] and is also in line with the lower frequency of ESBL
genes detected in K. variicola genome sequences, compared to K. pneumoniae genome sequences. As genes
encoding AMR are often carried on plasmids, this may
be linked to the lower median number of plasmids detected in isolates of K. variicola.
These findings need to be explored in other epidemiological situations with higher ESBL and carbapenemase
burdens to examine their broader relevance. With this, a
rapid and accurate species identification by MALDITOF MS may have an important impact on antibiotic
stewardship and treatment decisions.

Conclusions
Based on systematic comparison of WGS and in silico
ribosomal subunit protein mass prediction, we present a
MALDI-TOF MS-based analytical approach to
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distinguish eight Klebsiella species which can be applied
in clinical routine diagnostic laboratories. In this study,
we identified species-specific AMR and virulence patterns within the genus Klebsiella and uncovered an increased association of the K. oxytoca group with invasive
infection to primary sterile sites.
Abbreviations
AMR: Antimicrobial resistance; WGS: Whole-genome sequencing; MDR: Multidrug resistant; MALDI-TOF MS: Matrix-Assisted Laser Desorption Ionization Time Of Flight Mass Spectrometry; ANI: Average Nucleotide Identity;
CHCA: Cyano-4-hydroxycinnamic acid; ICU: Intensive care unit; CCI: Charlson
Comorbidity Index; GLMM: Generalized linear mixed models;
IQR: Interquartile range; OR: Odds ratio

Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13073-021-00960-5.
Additional file 1: Figure S1. Schematic representation of the workflow
of the project. Figure S2. Gene accumulation curves for species of the K.
pneumoniae group (A) and the K. oxytoca group (B). Figure S3. Genes
associated with AMR detected in Klebsiella spp.Figure S4. Partial least
squares discriminant analysis (PLS-DA) score plot containing primary
metabolites measured of five Klebsiella spp.Figure S5. Species identity of
datasets (a), (b) and (c) included in the statistical analysis.
Additional file 2: Table S1. Strains included in the study and where
sequence data can be accessed.
Additional file 3. Supplementary methods for: Measurement of primary
metabolites. Fatty acid analysis. Statistical analysis of clinical outcome data.
Additional file 4: Table S2. Cellular fatty acid composition of 11
Klebsiella spp. strains.
Additional file 5: Table S3. Biochemical reaction and AMR profiles of a
diverse set of Klebsiella spp. Strains.
Additional file 6: Table S4. Reproducibility of detection for the predicted
ribosomal subunits in MALDI-TOF mass spectra acquired in 4 different centers.
Additional file 7: Table S5. Binary table displaying the predicted
ribosomal subunits mass variants and whether this variant was predicted
from an assembly or not.
Additional file 8: Table S6. Binary table of the protein marker masses
which can reproducibly be detected in MALDI-TOF MS spectra.
Additional file 9: Odds ratio estimates comparing Klebsiella groups and
species for resistance to different antibiotic classes: Table S7. Penicillins
with beta-lactamase Inhibitors. Table S8. 3rd-generation cephalosporins.
Table S9. 4th-generation cephalosporins. Table S10. Aminoglycosides.
Additional file 10: Summary data compiled for the statistical analysis of
clinical endpoints: Table S11. Summary of outcome variables for the
clinical data set. Table S12. Summary of explanatory variables for the
clinical data set.
Statistical analyses examining differences in clinical outcome between
the Klebsiella groups and species: Table S13. Odds ratio estimates from
the generalized linear mixed-effects model (GLMM) for all cause death
within 30 days from diagnosis. Table S14. Odds ratio estimates from the
generalized linear mixed-effects model (GLMM) for ICU admission. Table
S15. Hazard ratio estimates from cause-specific hazards Cox proportional
hazards model for time to death within hospital after diagnosis with hospital discharge as competing event. Table S16. Estimates of the multiplicative effects from the Poisson generalized linear mixed-effects model
(GLMM) for the number of medical disciplines involved. Table S17. Odds
ratio estimates from the generalized linear mixed-effects model (GLMM)
for the mentioning of the infection in the patient letter.
Acknowledgements
We thank Josiane Reist for MALDI-TOF MS measurements (University of Basel). We thank Magdalena Schneider, Christine Kiessling, Elisabeth Schultheiss,

Page 14 of 16

Rosa-Maria Vesco and Clarisse Straub for the DNA extraction, library preparations and sequencing of the bacterial isolates (all University Hospital Basel).
Furthermore, we thank the Functional Genomics Center Zurich for the PacBio
sequencing, and sciCORE for the computational infrastructure provided.
Authors’ contributions
Conceptualization: AC, DW, HSS, CO, CG, FF, RM, GR, AK, DRV, SvF, SB, STS,
TH, GS, CH, CC, JMG, OS, BRS, FM, MA, VG, HvD, GK, CM, CD, VP, AE. Data
Curation: AC, DW, HSS, CO, CG, FF, RM, AK, DRV, SvF, SB, STS, SH, GS, CH, CC,
JMG, OS, BRS, FM, MA, VG, HvD, GK, CM, VP. Formal analysis: AC, DW, HSS, FF,
DRV, SvF, TH, CC, VP. Funding acquisition: CD, VP, AE. Investigation: AC, CO,
CG, RM, TH, CC, VP. Methodology: AC, RM, FF, CH, VP, AE. Project
administration: AC, CD, VP, AE. Resources: GR, AK, SB, STS, JMG, OS, BRS, FM,
MA, VG, HvD, GK, CM, AE. Software: AC, DW, HSS, FF, DRV, SvF. Supervision:
CD, VP, AE. Validation: AC, DW, HSS, CO, CG, FF, RM, GR, AK, DRV, SvF, SB, STS,
TH, GS, CH, CC, JMG, OS, BRS, FM, MA, VG, HvD, GK, CM, CD, VP, AE.
Visualization: AC, DW, HSS, DRV, SvF, TH. Writing – original draft preparation:
AC. Writing – review & editing: AC, DW, HSS, CO, CG, FF, RM, GR, AK, DRV,
SvF, SB, STS, TH, GS, CH, CC, JMG, OS, BRS, FM, MA, VG, HvD, GK, CM, CD, VP,
AE. All authors read and approved the final manuscript.
Funding
This study was supported by a “Personalized Health” at ETHZ (D-BSSE) and
University of Basel grant (PMB-03-17) granted to AE and a Doc.Mobility
Fellowship by the Swiss National Science Foundation (P1BSP3-184342)
granted to AC.
Availability of data and materials
Whole-genome sequences acquired for this study have been uploaded to
Genebank (https://www.ncbi.nlm.nih.gov/genbank/). Accession numbers of
these and previously published WGS data used in this study can be found in
Additional file 2: Table S1.
Software code generating figures from the genomic analysis is available on
GitHub (https://github.com/appliedmicrobiologyresearch/Klebsiella-spp) [40].

Declarations
Ethics approval and consent to participate
Bacterial strains have been collected in clinical routine diagnostics. The
collection of bacterial strains and their analysis for diagnostic assay
development do not fall under the Swiss human research act and no ethical
approval nor consent to participate from patients was required. The analysis
of patient demographic and clinical outcome data was approved by the
“Ethikkommission Nordwest- und Zentralschweiz” (EKNZ) (BASEC-Nr. 201601899 and 2018-00225) for patients who did not reject the hospitals general
research consent. Patients who did reject the hospital’s general consent were
excluded from all analyses which include patient demographic and clinical
outcome data.
All analyses performed in this study were in accordance with the Helsinki
Declaration and its later amendments.
Consent for publication
Not applicable.
Competing interests
VP, FF and RM are employees of the company Mabritec AG, Riehen,
Switzerland, which commercializes ribosomal marker-based approaches in
MALDI-TOF MS data analyses for identification of microorganisms. FM, MA
(Labor Team W AG) and CM (Laborgemeinschaft 1) are employed by private
diagnostic laboratories. The remaining authors declare that they have no
competing interests.
Author details
Applied Microbiology Research, Department of Biomedicine, University of
Basel, Hebelstrasse 20, 4031 Basel, Switzerland. 2Division of Clinical
Bacteriology and Mycology, University Hospital Basel, Petersgraben 4, 4031
Basel, Switzerland. 3Swiss Institute for Bioinformatics, Basel, Switzerland.
4
Division of Internal Medicine, University Hospital Basel, Basel, Switzerland.
5
Mabritec AG, Riehen, Switzerland. 6Aga Khan University Hospital, Nairobi,
Kenya. 7Department of Clinical Research, University of Basel and University
Hospital Basel, Basel, Switzerland. 8Department of Biostatistics, Epidemiology,
1

Cuénod et al. Genome Medicine

(2021) 13:150

Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich,
Switzerland. 9Division of Infectious Diseases and Hospital Epidemiology,
University Hospital Basel, Basel, Switzerland. 10Department of Clinical
Research, University of Basel, Basel, Switzerland. 11Division of Instrumental
Analytics, School of Applied Sciences (FHNW), Muttenz, Switzerland.
12
Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
13
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva,
Israel. 14Soroka University Medical Center, Beer Sheva, Israel. 15Hospital
General Universitario Gregorio Marañón, Madrid, Spain. 16Servicio de
Microbiología Clínica y Enfermedades Infecciosas, Hospital General
Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio
Marañón, Madrid, Spain. Instituto de Investigación Sanitaria Gregorio
Marañón, Madrid, Spain. 17Labor Team W AG, Goldach, Switzerland. 18Servizio
di microbiologia EOLAB, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
19
Department of Medical Microbiology, Maastricht University Medical Center,
Maastricht, the Netherlands. 20Department of Medical Microbiology &
Infection prevention, University of Groningen, Groningen, the Netherlands.
21
University Medical Center Groningen (UMCG), Groningen, the Netherlands.
22
Laborgemeinschaft 1, Zurich, Switzerland. 23Swiss Tropical and Public
Health Institute, Basel, Switzerland. 24Department of Sciences, University of
Basel, Basel, Switzerland.

Page 15 of 16

15.
16.

17.
18.

19.

20.

Received: 8 April 2021 Accepted: 27 August 2021
21.
References
1. Gorrie CL, Mirčeta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al.
Gastrointestinal carriage is a major reservoir of Klebsiella pneumoniae
infection in intensive care patients. Clin Infect Dis. 2017;65(2):208–15.
2. Martin RM, Bachman MA. Colonization, infection, and the accessory
genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8:4.
3. Siu LK, Yeh K-M, Lin J-C, Fung C-P, Chang F-Y. Klebsiella pneumoniae liver
abscess: a new invasive syndrome. Lancet Infect Dis. 2012;12(11):881–7.
4. Struve C, Roe CC, Stegger M, Stahlhut SG, Hansen DS, Engelthaler DM, et al.
Mapping the evolution of hypervirulent Klebsiella pneumoniae. mBio. 2015;
6(4) [cited 2017 Dec 5]. Available from: https://www.ncbi.nlm.nih.gov/pmc/a
rticles/PMC4513082/.
5. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic
of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by
nosocomial spread. Nat Microbiol. 2019;4(11):1919–29.
6. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT,
Andrasević AT, et al. Occurrence of carbapenemase-producing Klebsiella
pneumoniae and Escherichia coli in the European survey of
carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective,
multinational study. Lancet Infect Dis. 2017;17(2):153–63.
7. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL,
et al. Discovery, research, and development of new antibiotics: the WHO
priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis.
2018;18(3):318–27.
8. Rodrigues C, Passet V, Rakotondrasoa A, Brisse S. Identification of Klebsiella
pneumoniae, Klebsiella quasipneumoniae, Klebsiella variicola and Related
Phylogroups by MALDI-TOF Mass Spectrometry. Front Microbiol. 2018;9
[cited 2019 Oct 3]. Available from: https://www.frontiersin.org/articles/10.33
89/fmicb.2018.03000/full.
9. Rosenblueth M, Martínez L, Silva J, Martínez-Romero E. Klebsiella variicola, a
novel species with clinical and plant-associated isolates. Syst Appl Microbiol.
2004;27(1):27–35.
10. Long SW, Linson SE, Saavedra MO, Cantu C, Davis JJ, Brettin T, et al. Wholegenome sequencing of a human clinical isolate of the novel species
Klebsiella quasivariicola sp. nov. Genome Announc. 2017;5(42):e01057–17.
11. Rodrigues C, Passet V, Rakotondrasoa A, Diallo TA, Criscuolo A, Brisse S.
Description of Klebsiella africanensis sp. nov., Klebsiella variicola subsp.
tropicalensis subsp. nov. and Klebsiella variicola subsp. variicola subsp. nov.
Res Microbiol. 2019;170(3):165–70.
12. Saha R, Farrance CE, Verghese B, Hong S, Donofrio RS. Klebsiella
michiganensis sp. nov., a new bacterium isolated from a tooth brush holder.
Curr Microbiol. 2013;66(1):72–8.
13. Passet V, Brisse S. Description of Klebsiella grimontii sp. nov. Int J Syst Evol
Microbiol. 2018;68(1):377–81.
14. Merla C, Rodrigues C, Passet V, Corbella M, Thorpe HA, Kallonen TVS, et al.
Description of Klebsiella spallanzanii sp. nov. and of Klebsiella pasteurii sp.

22.
23.
24.

25.

26.

27.
28.
29.

30.

31.

32.

33.

34.
35.

36.

nov. Front Microbiol. 2019;10 [cited 2021 Jan 14]. Available from: https://
www.frontiersin.org/articles/10.3389/fmicb.2019.02360/full.
Hu Y, Wei L, Feng Y, Xie Y, Zong Z. Klebsiella huaxiensis sp. nov., recovered
from human urine. Int J Syst Evol Microbiol. 2019;69(2):333–6.
Long SW, Linson SE, Ojeda Saavedra M, Cantu C, Davis JJ, Brettin T, et al.
Whole-genome sequencing of human clinical Klebsiella pneumoniae
isolates reveals misidentification and misunderstandings of Klebsiella
pneumoniae, Klebsiella variicola, and Klebsiella quasipneumoniae. mSphere.
2017;2(4) [cited 2017 Oct 27]. Available from: https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC5541162/.
Iwase T, Ogura Y, Hayashi T, Mizunoe Y. Complete genome sequence of
Klebsiella oxytoca strain JKo3. Genome Announc. 2016;4(6):e01221–16.
Herzog KAT, Schneditz G, Leitner E, Feierl G, Hoffmann KM, Zollner-Schwetz I,
et al. Genotypes of Klebsiella oxytoca isolates from patients with nosocomial
pneumonia are distinct from those of isolates from patients with antibioticassociated hemorrhagic colitis. J Clin Microbiol. 2014;52(5):1607–16.
Leitner E, Zarfel G, Luxner J, Herzog K, Pekard-Amenitsch S, Hoenigl M, et al.
Contaminated handwashing sinks as the source of a clonal outbreak of
KPC-2-producing Klebsiella oxytoca on a hematology ward. Antimicrobial
Agents Chemother. 2015;59(1):714–6.
Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, et al.
Genomic analysis of diversity, population structure, virulence, and
antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public
health. PNAS. 2015;112(27):E3574–81.
Moradigaravand D, Martin V, Peacock SJ, Parkhill J. Population structure of
multidrug-resistant Klebsiella oxytoca within hospitals across the United
Kingdom and Ireland identifies sharing of virulence and resistance genes
with K. pneumoniae. Genome Biol Evol. 2017;9(3):574–84.
Fontana L, Bonura E, Lyski Z, Messer W. The Brief Case: Klebsiella
variicola—identifying the misidentified. J Clin Microbiol. 2019;57(1):e00826–18.
Mollet C, Drancourt M, Raoult D. rpoB sequence analysis as a novel basis for
bacterial identification. Mol Microbiol. 1997;26(5):1005–11.
Angeletti S. Matrix assisted laser desorption time of flight mass
spectrometry (MALDI-TOF MS) in clinical microbiology. J Microbiol Methods.
2017;138:20–9.
Dinkelacker AG, Vogt S, Oberhettinger P, Mauder N, Rau J, Kostrzewa M,
et al. Typing and species identification of clinical Klebsiella isolates by
Fourier transform infrared spectroscopy and Matrix-Assisted Laser
Desorption Ionization–Time of Flight Mass Spectrometry. J Clin Microbiol.
2018;56(11):e00843–18.
Bridel S, Watts SC, Judd LM, Harshegyi T, Passet V, Rodrigues C, et al.
Klebsiella MALDI TypeR: a web-based tool for Klebsiella identification based
on MALDI-TOF mass spectrometry. Res Microbiol. 2021;15:103835.
Anhalt JP, Catherine F. Identification of bacteria using mass spectrometry.
Anal Chem. 1975;47(2):219–25.
Ryzhov V, Fenselau C. Characterization of the protein subset desorbed by
MALDI from whole bacterial cells. Anal Chem. 2001;73(4):746–50.
Ojima-Kato T, Yamamoto N, Suzuki M, Fukunaga T, Tamura H. Discrimination
of Escherichia coli O157, O26 and O111 from other serovars by MALDI-TOF
MS based on the S10-GERMS method. PLoS One. 2014;9(11):e113458.
Rothen J, Pothier JF, Foucault F, Blom J, Nanayakkara D, Li C, et al.
Subspecies typing of Streptococcus agalactiae based on ribosomal subunit
protein mass variation by MALDI-TOF MS. Front Microbiol. 2019;10 [cited
2019 May 17]. Available from: https://www.frontiersin.org/article/10.3389/
fmicb.2019.00471/full.
Richter M, Rosselló-Móra R. Shifting the genomic gold standard for the
prokaryotic species definition. Proc Natl Acad Sci U S A. 2009;106:19126–31.
https://doi.org/10.1073/pnas.0906412106.
Andrews S. FastQC: a quality control tool for high throughput sequence
data [Online]. 2010. Available online at: http://www.bioinformatics.babraha
m.ac.uk/projects/fastqc/.
Truong DT, Tett A, Pasolli E, Huttenhower C, Segata N. Microbial strain-level
population structure and genetic diversity from metagenomes. Genome
Res. 2017;27(4):626–38.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
sequence data. Bioinformatics. 2014;30(15):2114–20.
Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome
assemblies from short and long sequencing reads. PLoS Comput Biol. 2017;
13(6):e1005595.
Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics.
2014;30(14):2068–9.

Cuénod et al. Genome Medicine

(2021) 13:150

37. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al.
Roary: rapid large-scale prokaryote pan genome analysis. Bioinformatics.
2015;31(22):3691–3.
38. Price MN, Dehal PS, Arkin AP. FastTree: computing large minimum evolution
trees with profiles instead of a distance matrix. Mol Biol Evol. 2009;26(7):
1641–50.
39. Price MN, Dehal PS, Arkin AP. FastTree 2 – approximately maximumlikelihood trees for large alignments. PLoS One. 2010;5(3):e9490.
40. Wüthrich D, Cuénod A. Klebsiella-spp. GitHub. 2021 [cited 2021 Aug 23].
Available from: https://github.com/appliedmicrobiologyresearch/Klebsiella-spp.
41. Lam MMC, Wyres KL, Judd LM, Wick RR, Jenney A, Brisse S, et al. Tracking
key virulence loci encoding aerobactin and salmochelin siderophore
synthesis in Klebsiella pneumoniae. bioRxiv. 2018;25:376236.
42. Wyres KL, Wick RR, Gorrie C, Jenney A, Follador R, Thomson NR, et al.
Identification of Klebsiella capsule synthesis loci from whole genome data.
Microb Genom. 2016;2(12) [cited 2017 Oct 27]. Available from: https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC5359410/.
43. Wick RR, Heinz E, Holt KE, Wyres KL. Kaptive Web: user-friendly capsule and
lipopolysaccharide serotype prediction for Klebsiella genomes. J Clin
Microbiol. 2018;56(6):e00197–18.
44. Schneditz G, Rentner J, Roier S, Pletz J, Herzog KAT, Bücker R, et al.
Enterotoxicity of a nonribosomal peptide causes antibiotic-associated colitis.
PNAS. 2014;111(36):13181–6.
45. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L,
et al. In silico detection and typing of plasmids using PlasmidFinder and
plasmid multilocus sequence typing. Antimicrob Agents Chemother. 2014;
58(7):3895–903.
46. Seemann T. Abricate. https://github.com/tseemann/abricate;
47. Varshavsky A. The N-end rule pathway and regulation by proteolysis. Protein
Sci. 2011;20(8):1298–345.
48. Wynne C, Fenselau C, Demirev PA, Edwards N. Top-down identification of
protein biomarkers in bacteria with unsequenced genomes. Anal Chem.
2009;81(23):9633–42.
49. Gibb S, Strimmer K. MALDIquant: a versatile R package for the analysis of
mass spectrometry data. Bioinformatics. 2012;28(17):2270–1.
50. The European Committee on Antimicrobial Susceptibility Testing. The
European Committee on Antimicrobial Susceptibility Testing. Breakpoint
tables for interpretation of MICs and zone diameters, version 6.0-8.1, 2016 2018 [Internet]. 2016. Available from: http://www.eucast.org/clinical_brea
kpoints/.
51. Gasser M, Schrenzel J, Kronenberg A. Aktuelle Entwicklung der
Antibiotikaresistenzen in der Schweiz. Swiss Med Forum. 2018;18(46):943–9.
52. Iucif N, Rocha JSY. Study of inequalities in hospital mortality using the
Charlson comorbidity index. Rev Saude Publica. 2004;38(6):780–6.
53. Wyres KL, Holt KE. Klebsiella pneumoniae as a key trafficker of drug
resistance genes from environmental to clinically important bacteria
[Internet]. PeerJ Inc.; 2018. Report No.: e26852v1. [cited 2019 Feb 15].
Available from: https://peerj.com/preprints/26852.
54. Wyres KL, Wick RR, Judd LM, Froumine R, Tokolyi A, Gorrie CL, et al. Distinct
evolutionary dynamics of horizontal gene transfer in drug resistant and
virulent clones of Klebsiella pneumoniae. PLoS Genet. 2019;15(4):e1008114.
55. David S, Cohen V, Reuter S, Sheppard AE, Giani T, Parkhill J, et al. Integrated
chromosomal and plasmid sequence analyses reveal diverse modes of
carbapenemase gene spread among Klebsiella pneumoniae. PNAS. 2020;
117(40):25043–54.
56. Nagy ZA, Szakács D, Boros E, Héja D, Vígh E, Sándor N, et al. Ecotin, a
microbial inhibitor of serine proteases, blocks multiple complement
dependent and independent microbicidal activities of human serum. PLoS
Pathog. 2019;15(12):e1008232.
57. Hæggman S, Löfdahl S, Paauw A, Verhoef J, Brisse S. Diversity and evolution
of the class A chromosomal beta-lactamase gene in Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2004;48(7):2400–8.
58. Granier SA, Leflon-Guibout V, Goldstein FW, Nicolas-Chanoine M-H. New
Klebsiella oxytoca β-lactamase genes blaOXY-3 and blaOXY-4 and a third
genetic group of K. oxytoca based on blaOXY-3. Antimicrob Agents
Chemother. 2003;47(9):2922–8.
59. Cuénod A, Foucault F, Pflüger V, Egli A. Factors associated with MALDI-TOF
mass spectral quality of species identification in clinical routine diagnostics.
Front Cell Infect Microbiol. 2021;11 [cited 2021 Mar 17]. Available from:
https://www.frontiersin.org/articles/10.3389/fcimb.2021.646648/full.

Page 16 of 16

60. Bridel S, Watts SC, Judd LM, Harshegyi T, Passet V, Rodrigues C, et al.
Klebsiella MALDI TypeR: a web-based tool for Klebsiella identification based
on MALDI-TOF mass spectrometry. bioRxiv. 2020;13:2020.10.13.337162.
61. Lawlor MS, O’Connor C, Miller VL. Yersiniabactin is a virulence factor for
Klebsiella pneumoniae during pulmonary infection. IAI. 2007;75(3):1463–72.
62. Chou H-C, Lee C-Z, Ma L-C, Fang C-T, Chang S-C, Wang J-T. Isolation of a
chromosomal region of Klebsiella pneumoniae associated with allantoin
metabolism and liver infection. Infect Immun. 2004;72(7):3783–92.
63. Lam MMC, Wick RR, Wyres KL, Gorrie CL, Judd LM, Jenney AWJ, et al.
Genetic diversity, mobilisation and spread of the yersiniabactin-encoding
mobile element ICEKp in Klebsiella pneumoniae populations. Microbial
Genomics. 2018;4(9) [cited 2019 Jan 11]. Available from: http://www.
microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000196.
64. Maatallah M, Vading M, Kabir MH, Bakhrouf A, Kalin M, Nauclér P, et al.
Klebsiella variicola is a frequent cause of bloodstream infection in the
Stockholm area, and associated with higher mortality compared to K.
pneumoniae. PLoS One. 2014;9(11):e113539.
65. Brisse S, van Himbergen T, Kusters K, Verhoef J. Development of a rapid
identification method for Klebsiella pneumoniae phylogenetic groups and
analysis of 420 clinical isolates. Clin Microbiol Infect. 2004;10(10):942–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

